• Markets
    • icon
  • Companies
IXC · ASX

Invex Therapeutics Ltd. (ASX:IXC)

AU$0.24

 0.0 (0.0%)
ASX:Live
01/12/2023 04:10:47 PM
Near Resistance HALO Ords GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

IXC Overview

IXC Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About IXC

Website

Invex Therapeutics Ltd.

Telephone

N/A

Address

Description

Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. It focuses in understanding and defining the mechanisms that regulate pressure in the brain and aims to repurpose and reformulate an already approved drug, Exenatide. The company was founded by Jason Loveridge and Alexandra J. Sinclair on March 8, 2019 and is headquartered in Subiaco, Australia.

IXC Price Chart

Key Stats

Market Cap

AU$18.04M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.15 - 0.66

Trade Value (12mth)

AU$9,705.00

1 week

4.35%

1 month

11.63%

YTD

-57.14%

1 year

-58.97%

All time high

2.05

Key Fundamentals

EPS 3 yr Growth

72.400%

EBITDA Margin

N/A

Operating Cashflow

-$7m

Free Cash Flow Return

-27.60%

ROIC

-31.20%

Interest Coverage

N/A

Quick Ratio

14.50

Other Data

Shares on Issue (Fully Dilluted)

75m

HALO Sector

Healthcare

Next Company Report Date

15-Aug-24

Ex Dividend Date (est.)

08-Dec-23

Next Dividend Pay Date (est.)

18-Dec-23

Reporting Currency

AUD

Short Sell (% of issue)

0.00

IXC Announcements

Latest Announcements

Date Announcements

31 January 22

New Executive Director and Chairman Agreements

×

New Executive Director and Chairman Agreements

31 August 23

Becoming a substantial holder

×

Becoming a substantial holder

30 September 22

Second HREC Approval for IIH EVOLVE Phase III Clinical Trial

×

Second HREC Approval for IIH EVOLVE Phase III Clinical Trial

30 November 23

Payment of Capital Return Proceeds

×

Payment of Capital Return Proceeds

30 November 22

Invex to Present at the MST Financial Biotech Forum

×

Invex to Present at the MST Financial Biotech Forum

29 June 22

Invex Receives UK Approval to Commence Phase III Trial

×

Invex Receives UK Approval to Commence Phase III Trial

29 June 20

Presentation of Exenatide Phase II Data at Headache Congress

×

Presentation of Exenatide Phase II Data at Headache Congress

28 September 23

Change in substantial holding

×

Change in substantial holding

28 November 23

Change in substantial holding

×

Change in substantial holding

28 November 23

Chair's Address to Shareholders

×

Chair's Address to Shareholders

28 November 23

Results of Meeting

×

Results of Meeting

28 June 23

Phase III Clinical Trial Update and New IIH Market Analysis

×

Phase III Clinical Trial Update and New IIH Market Analysis

28 August 20

Appendix 4E and Annual Report

×

Appendix 4E and Annual Report

27 September 21

Notice of Investor Call and Presentation

×

Notice of Investor Call and Presentation

27 October 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

27 November 23

Change of Director's Interest Notice x 3

×

Change of Director's Interest Notice x 3

27 August 21

Appendix 4E and Annual Report

×

Appendix 4E and Annual Report

26 October 22

Upcoming Presentation at Argonaut Biotech Briefing

×

Upcoming Presentation at Argonaut Biotech Briefing

25 September 23

Date of AGM and Closing Date for Director Nominations

×

Date of AGM and Closing Date for Director Nominations

25 October 21

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

25 November 22

MEDSAFE and Ethics Approval for IIH EVOLVE Trial in NZ

×

MEDSAFE and Ethics Approval for IIH EVOLVE Trial in NZ

25 January 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

25 August 23

Change of Director's Interest Notice

×

Change of Director's Interest Notice

24 October 22

First Australian Site Activated in IIH EVOLVE Phase 3

×

First Australian Site Activated in IIH EVOLVE Phase 3

24 October 22

First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial

×

First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial

24 October 22

September Appendix 4C and Investor Conference Call Details

×

September Appendix 4C and Investor Conference Call Details

24 January 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

IXC Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.03 -0.05 -0.10 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.03 -0.05 -0.10 Lock Lock Lock
     Growth % Lock Lock Lock Lock 49.2 -73.0 -96.0 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.05 -0.10 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.02 -0.04 -0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock 31.8 -109.2 -101.5 Lock Lock Lock
     Yield % Lock Lock Lock Lock -3.5 -9.1 -45.7 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.43 0.38 0.28 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.43 0.38 0.28 Lock Lock Lock
     Growth % Lock Lock Lock Lock 18.1 -11.2 -25.5 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 75 75 75 Lock Lock Lock
Basic m Lock Lock Lock Lock 75 75 75 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 2 4 9 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -2 -4 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock 28.3 -71.5 -115.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -2 -4 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock 28.3 -71.5 -115.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -2 -4 -8 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -2 -4 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock 32.0 -73.1 -96.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -2 -3 -7 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 8 0 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -2 -3 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -4.7 -101.2 -103.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 33 29 22 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 33 29 23 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -33 -29 -22 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 1 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 32 28 21 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 32 28 21 Lock Lock Lock
     Growth % Lock Lock Lock Lock 31.5 -11.2 -25.5 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -7.0 -13.4 -34.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -7.1 -13.9 -36.5 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -8.6 -13.8 -36.3 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -8.1 -13.1 -31.2 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -5.9 -11.2 -27.6 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 13.4 7.0 2.5 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -102.0 -103.0 -105.8 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 49.7 29.4 14.5 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 49.7 29.4 14.5 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 99.9 99.5 98.5 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -254.8 -336.3 -436.9 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -7.0 -13.4 -34.0 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.0 1.0 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -7.1 -13.9 -36.5 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -7.1 -13.9 -36.5 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

08-Dec-23

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

IXC Shortsell

Frequently Asked Questions

The current share price of Invex Therapeutics Ltd. (IXC:ASX) is AU$0.24.
The 52-week high share price for Invex Therapeutics Ltd. (IXC:ASX) is AU$0.66.
The 52-week low share price for Invex Therapeutics Ltd. (IXC:ASX)? is AU$0.15.
Invex Therapeutics Ltd. (IXC:ASX) does not pay a dividend.
Invex Therapeutics Ltd. (IXC:ASX) does not pay a dividend.
Invex Therapeutics Ltd. (IXC:ASX) has a franking level of 0%.
Invex Therapeutics Ltd. (IXC:ASX) is classified in the Healthcare.
The current P/E ratio for Invex Therapeutics Ltd. (IXC:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.